Empire Financial Management Company LLC Trims Stock Position in Vanda Pharmaceuticals Inc. $VNDA

Empire Financial Management Company LLC cut its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 16.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 922,245 shares of the biopharmaceutical company’s stock after selling 186,000 shares during the quarter. Vanda Pharmaceuticals comprises about 1.4% of Empire Financial Management Company LLC’s holdings, making the stock its 14th biggest holding. Empire Financial Management Company LLC’s holdings in Vanda Pharmaceuticals were worth $6,373,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Renaissance Technologies LLC boosted its stake in shares of Vanda Pharmaceuticals by 11.2% during the 1st quarter. Renaissance Technologies LLC now owns 3,759,559 shares of the biopharmaceutical company’s stock valued at $25,979,000 after purchasing an additional 378,598 shares in the last quarter. Vanguard Group Inc. raised its stake in Vanda Pharmaceuticals by 0.4% in the third quarter. Vanguard Group Inc. now owns 3,587,139 shares of the biopharmaceutical company’s stock worth $17,900,000 after buying an additional 14,336 shares in the last quarter. AIGH Capital Management LLC raised its stake in Vanda Pharmaceuticals by 37.6% in the first quarter. AIGH Capital Management LLC now owns 2,750,000 shares of the biopharmaceutical company’s stock worth $19,002,000 after buying an additional 751,569 shares in the last quarter. Millennium Management LLC lifted its holdings in Vanda Pharmaceuticals by 220.0% in the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock worth $9,821,000 after buying an additional 1,470,898 shares during the period. Finally, Krensavage Asset Management LLC boosted its position in Vanda Pharmaceuticals by 15.2% during the 3rd quarter. Krensavage Asset Management LLC now owns 1,180,388 shares of the biopharmaceutical company’s stock valued at $5,890,000 after acquiring an additional 155,505 shares in the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Stock Down 1.1%

Shares of Vanda Pharmaceuticals stock opened at $5.16 on Wednesday. Vanda Pharmaceuticals Inc. has a 1 year low of $4.14 and a 1 year high of $9.94. The firm has a market cap of $310.30 million, a price-to-earnings ratio of -1.27 and a beta of 0.60. The company has a 50-day moving average of $5.97 and a 200 day moving average of $6.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.16 and a quick ratio of 2.15.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.13). Vanda Pharmaceuticals had a negative return on equity of 32.26% and a negative net margin of 109.99%.The business had revenue of $51.72 million for the quarter, compared to the consensus estimate of $54.98 million. As a group, sell-side analysts anticipate that Vanda Pharmaceuticals Inc. will post -2.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

VNDA has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Thursday, June 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th. Finally, Wall Street Zen lowered Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.30.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.